1,076 Shares of IDEXX Laboratories, Inc. $IDXX Bought by R Squared Ltd

R Squared Ltd acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,076 shares of the company’s stock, valued at approximately $562,000.

Other institutional investors also recently modified their holdings of the company. Three Bridge Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at approximately $80,000. UNIVEST FINANCIAL Corp lifted its holdings in IDEXX Laboratories by 3.5% during the 3rd quarter. UNIVEST FINANCIAL Corp now owns 8,358 shares of the company’s stock worth $4,364,000 after buying an additional 282 shares in the last quarter. Jacobi Capital Management LLC acquired a new position in IDEXX Laboratories during the 3rd quarter worth $191,000. Jefferies Financial Group Inc. boosted its position in IDEXX Laboratories by 659.7% in the 3rd quarter. Jefferies Financial Group Inc. now owns 11,380 shares of the company’s stock valued at $5,943,000 after buying an additional 9,882 shares during the last quarter. Finally, First Command Advisory Services Inc. boosted its position in IDEXX Laboratories by 36.8% in the 3rd quarter. First Command Advisory Services Inc. now owns 364 shares of the company’s stock valued at $190,000 after buying an additional 98 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday, October 16th. BTIG Research dropped coverage on IDEXX Laboratories in a report on Friday, October 30th. They issued a “buy” rating on the stock. UBS Group lifted their price objective on IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. Morgan Stanley lifted their price objective on IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 3rd. Finally, The Goldman Sachs Group initiated coverage on IDEXX Laboratories in a report on Friday, October 16th. They set a “buy” rating and a $740.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $717.27.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $698.02 on Friday. The firm’s 50 day moving average price is $558.91 and its two-hundred day moving average price is $573.47. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.88 and a current ratio of 1.19. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The stock has a market cap of $55.00 billion, a PE ratio of 47.07 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.71 by $0.25. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.22 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Michael Lane sold 3,979 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $688.64, for a total value of $2,740,098.56. Following the completion of the sale, the executive vice president owned 4,076 shares in the company, valued at approximately $2,806,896.64. This represents a 49.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Sharon Underberg sold 8,906 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $688.59, for a total value of $6,132,582.54. Following the completion of the transaction, the executive vice president directly owned 7,169 shares in the company, valued at $4,936,501.71. The trade was a 55.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 41,428 shares of company stock valued at $28,567,934 over the last quarter. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.